|
Characteristic
|
Long- term survivors ≥8 years
|
Short-term survivors <8 years
|
|---|
|
No. of patients (%)
|
|
Mean age (years)
|
55 (27–73)
|
51 (33–72)
|
|
Histologic type
| | |
|
Invasive ductal
|
33 (82.5)
|
31 (77.5)
|
|
Invasive lobular
|
3 (7.5)
|
7 (17.5)
|
|
Invasive ductal + lobular
|
0 (0)
|
1 (2.5)
|
|
Other
|
3 (7.5)
|
1 (2.5)
|
|
Not available
|
1 (2.5)
|
0 (0)
|
|
Pathologic tumor size (mm)
| | |
|
pT1 (0–20)
|
8 (20)
|
8 (20)
|
|
pT2 (>20-50)
|
27 (67.5)
|
29 (72.5)
|
|
pT3 (>50)
|
5 (12.5)
|
3 (7.5)
|
|
BRE grade
| | |
|
I-II
|
21 (100)
|
20 (100)
|
|
III
|
19 (100)
|
20 (100)
|
|
No. of axillary lymph nodes
| | |
|
0
|
14 (35)
|
14 (35)
|
|
1-3
|
12 (30)
|
12 (30)
|
|
≥4
|
14 (35)
|
14 (35)
|
|
ER/PR receptor
| | |
|
Negative
|
19 (47.5)
|
20 (50)
|
|
Positive
|
20 (50)
|
20 (50)
|
|
Not available
|
1 (2.5)
|
0 (0)
|
|
HER2 status
| | |
|
Positive
|
15 (37.5)
|
11 (27.5)
|
|
Negative
|
21 (52.5)
|
20 (50)
|
|
Not available
|
4 (10)
|
9 (22.5)
|
|
Surgery
| | |
|
Lumpectomy
|
15 (37.5)
|
15 (37.5)
|
|
Mastectomy
|
25 (62.5)
|
25 (62.5)
|
|
Radiotherapy
| | |
|
No
|
19 (86)
|
19 (47.5)
|
|
Yes
|
11 (20)
|
20 (50)
|
|
Not available
|
2 (9)
|
1 (2.5)
|
|
Chemotherapy
| | |
|
No
|
12 (36.5)
|
16 (41)
|
|
Yes
|
17 (51.5)
|
23 (59)
|
|
Not available
|
4 (12)
|
0 (0)
|
|
Endocrine therapy
| | |
|
No
|
15 (45.5)
|
20 (51)
|
|
Yes
|
13 (39.5)
|
18 (46)
|
|
Not available
|
5 (15)
|
1 (3)
|
|
Recurrence
| | |
|
No
|
15 (45)
|
10 (25)
|
|
Yes
|
3 (10)
|
15 (37.5)
|
|
Not available
|
15 (45)
|
15 (37.5)
|
- BRE, Bloom, Richardson, Elston/Ellis; HR, hazard ratio; CI, confidence interval; ER/PR, Estrogen/Progesterone receptor. All parameters were coded as 0 (negative) and 1 (positive) except as noted. Histologic type was coded as 1 (ductal), 2 (lobular ductal), 3 (ductal and lobular) and 4 (other).
